UNLABELLED: The majority of patients with nonalcoholic fatty liver disease (NAFLD) have "simple steatosis," which is defined by hepatic steatosis in the absence of substantial inflammation or fibrosis and is considered to be benign. However, 10%-30% of patients with NAFLD progress to fibrosing nonalcoholic steatohepatitis (NASH), which is characterized by varying degrees of hepatic inflammation and fibrosis, in addition to hepatic steatosis, and can lead to cirrhosis. The cause(s) of progression to fibrosing steatohepatitis are unclear. We aimed to test the relative contributions of dietary fat and dietary cholesterol and their interaction on the development of NASH. We assigned C57BL/6J mice to four diets for 30 weeks: control (4% fat and 0% cholesterol); high cholesterol (HC; 4% fat and 1% cholesterol); high fat (HF; 15% fat and 0% cholesterol); and high fat, high cholesterol (HFHC; 15% fat and 1% cholesterol). The HF and HC diets led to increased hepatic fat deposition with little inflammation and no fibrosis (i.e., simple hepatic steatosis). However, the HFHC diet led to significantly more profound hepatic steatosis, substantial inflammation, and perisinusoidal fibrosis (i.e., steatohepatitis), associated with adipose tissue inflammation and a reduction in plasma adiponectin levels. In addition, the HFHC diet led to other features of human NASH, including hypercholesterolemia and obesity. Hepatic and metabolic effects induced by dietary fat and cholesterol together were more than twice as great as the sum of the separate effects of each dietary component alone, demonstrating significant positive interaction. CONCLUSION: Dietary fat and dietary cholesterol interact synergistically to induce the metabolic and hepatic features of NASH, whereas neither factor alone is sufficient to cause NASH in mice.
UNLABELLED: The majority of patients with nonalcoholic fatty liver disease (NAFLD) have "simple steatosis," which is defined by hepatic steatosis in the absence of substantial inflammation or fibrosis and is considered to be benign. However, 10%-30% of patients with NAFLD progress to fibrosing nonalcoholic steatohepatitis (NASH), which is characterized by varying degrees of hepatic inflammation and fibrosis, in addition to hepatic steatosis, and can lead to cirrhosis. The cause(s) of progression to fibrosing steatohepatitis are unclear. We aimed to test the relative contributions of dietary fat and dietary cholesterol and their interaction on the development of NASH. We assigned C57BL/6J mice to four diets for 30 weeks: control (4% fat and 0% cholesterol); high cholesterol (HC; 4% fat and 1% cholesterol); high fat (HF; 15% fat and 0% cholesterol); and high fat, high cholesterol (HFHC; 15% fat and 1% cholesterol). The HF and HC diets led to increased hepatic fat deposition with little inflammation and no fibrosis (i.e., simple hepatic steatosis). However, the HFHC diet led to significantly more profound hepatic steatosis, substantial inflammation, and perisinusoidal fibrosis (i.e., steatohepatitis), associated with adipose tissue inflammation and a reduction in plasma adiponectin levels. In addition, the HFHC diet led to other features of human NASH, including hypercholesterolemia and obesity. Hepatic and metabolic effects induced by dietary fat and cholesterol together were more than twice as great as the sum of the separate effects of each dietary component alone, demonstrating significant positive interaction. CONCLUSION: Dietary fat and dietary cholesterol interact synergistically to induce the metabolic and hepatic features of NASH, whereas neither factor alone is sufficient to cause NASH in mice.
Authors: Savitha Subramanian; Leela Goodspeed; Shari Wang; Jinkyu Kim; Lixia Zeng; George N Ioannou; W Geoffrey Haigh; Matthew M Yeh; Kris V Kowdley; Kevin D O'Brien; Subramaniam Pennathur; Alan Chait Journal: J Lipid Res Date: 2011-06-20 Impact factor: 5.922
Authors: Eric D Labonté; Lisa M Camarota; Juan C Rojas; Ronald J Jandacek; Dean E Gilham; Joanna P Davies; Yiannis A Ioannou; Patrick Tso; David Y Hui; Philip N Howles Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-08-21 Impact factor: 4.052
Authors: George N Ioannou; Savitha Subramanian; Alan Chait; W Geoffrey Haigh; Matthew M Yeh; Geoffrey C Farrell; Sum P Lee; Christopher Savard Journal: J Lipid Res Date: 2017-04-12 Impact factor: 5.922
Authors: Susan K Murphy; Hyuna Yang; Cynthia A Moylan; Herbert Pang; Andrew Dellinger; Manal F Abdelmalek; Melanie E Garrett; Allison Ashley-Koch; Ayako Suzuki; Hans L Tillmann; Michael A Hauser; Anna Mae Diehl Journal: Gastroenterology Date: 2013-07-31 Impact factor: 22.682
Authors: Priya Handa; Bryan D Maliken; James E Nelson; Vicki Morgan-Stevenson; Donald J Messner; Barjinderjit K Dhillon; Heather M Klintworth; Mary Beauchamp; Matthew M Yeh; Clinton T Elfers; Christian L Roth; Kris V Kowdley Journal: Hepatology Date: 2014-05-27 Impact factor: 17.425